Aura Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	41.08	121.6	149.09	17.41	32.47
Short-Term Investments	185.09	67.23	0	0	0
Cash & Cash Equivalents	226.17	188.83	149.09	17.41	32.47
Cash Growth	19.77%	26.66%	756.23%	-46.37%	-
Other Current Assets	5.63	7.87	4.62	1.04	0.88
Total Current Assets	231.79	196.7	153.7	18.46	33.35
Property, Plant & Equipment	22	26.04	6.2	3.57	3.63
Long-Term Investments	0.77	0.77	0.13	0.08	0.08
Other Long-Term Assets	0.51	0.42	0	0	0
Total Long-Term Assets	23.28	27.23	6.33	3.65	3.71
Total Assets	255.08	223.94	160.03	22.1	37.06
Accounts Payable	1.79	2.92	2.4	0.61	2.33
Current Debt	2.69	2.96	0.62	0	0
Other Current Liabilities	7.88	4.57	4.34	2.05	3.82
Total Current Liabilities	12.36	10.46	7.36	2.66	6.15
Long-Term Debt	16.87	17.9	0.36	0	0.05
Other Long-Term Liabilities	0	0	0	0.08	0.1
Total Long-Term Liabilities	16.87	17.9	0.36	0.08	0.14
Total Liabilities	29.23	28.35	7.72	2.74	6.29
Total Debt	19.56	20.86	0.98	0	0.05
Debt Growth	-6.24%	2039.28%	-	-	-
Retained Earnings	-287.31	-210.9	-152.14	-116.89	-94.68
Comprehensive Income	0.54	-0.07	0	0	0
Shareholders' Equity	225.85	195.58	152.32	-108.71	-87.41
Net Cash / Debt	206.61	167.97	148.11	17.41	32.42
Net Cash / Debt Growth	23.00%	13.41%	750.63%	-46.29%	-
Net Cash Per Share	5.21	5.61	28.70	47.42	6.99
Working Capital	219.44	186.25	146.35	15.79	27.2
Book Value Per Share	5.70	6.53	29.52	-296.06	-18.86

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).